川宁生物（301301）8月8日主力资金净流出4293.13万元

Core Viewpoint - The financial performance of Chuaning Biological (川宁生物) shows a decline in revenue and net profit for the first quarter of 2025, indicating potential challenges for the company moving forward [1]. Financial Performance - As of the first quarter of 2025, Chuaning Biological reported total revenue of 1.297 billion yuan, a year-on-year decrease of 14.85% [1]. - The net profit attributable to shareholders was 288 million yuan, down 18.26% year-on-year [1]. - The company's non-recurring net profit was 283 million yuan, reflecting a 19.55% decrease compared to the previous year [1]. - The liquidity ratios are as follows: current ratio at 2.239 and quick ratio at 1.648, indicating a strong liquidity position [1]. - The debt-to-asset ratio stands at 23.53%, suggesting a relatively low level of financial leverage [1]. Stock Performance - As of August 8, 2025, Chuaning Biological's stock closed at 12.2 yuan, down 1.21% with a turnover rate of 4.73% [1]. - The trading volume was 292,700 hands, with a total transaction value of 357 million yuan [1]. - There was a net outflow of main funds amounting to 42.93 million yuan, which accounted for 12.03% of the transaction value [1]. - Large orders saw a net outflow of 23.74 million yuan (6.65% of transaction value) and 19.19 million yuan (5.38% of transaction value) for big orders [1]. - Small orders experienced a net inflow of 46.36 million yuan, representing 12.99% of the transaction value [1]. Company Background - Chuaning Biological Technology Co., Ltd. was established in 2010 and is located in the Ili Kazakh Autonomous Prefecture [2]. - The company primarily engages in the pharmaceutical manufacturing industry [2]. - The registered capital of the company is 2.22716 billion yuan, with paid-in capital of approximately 1.98454 billion yuan [1][2]. - The legal representative of the company is Deng Xuheng [1]. Investment and Intellectual Property - Chuaning Biological has made investments in 14 companies and participated in 41 bidding projects [2]. - The company holds 9 trademark registrations and 154 patents, along with 41 administrative licenses [2].